BioSpace data show biopharma professionals faced increased competition for fewer employment opportunities during the second ...

The move comes after Robert F. Kennedy Jr. received pressure from the Children’s Health Defense, an anti-vaccine non-profit ...

Papzimeos is the first immunotherapy approved for recurrent respiratory papillomatosis, a rare lung disorder involving the ...

The Department of Health and Human Services’ mRNA pullback only applies to their use in upper respiratory disease, according ...

As Trump has pressured drugmakers to lower the cost of medicines in the U.S., the pharma industry has coalesced behind a ...

The Boston-based AI/ML startup focuses on endocrine and cardiometabolic diseases and will use that expertise to generate new ...

After two patients who received the investigational CDC7 blocker died, pushing forward with SGR-2921’s development would be ...

The death was linked to acute kidney injury in a patient who had a single kidney remaining and a “complex medical history,” ...

Vedanta is parting ways with 23 employees, or approximately 20% of its headcount, after Phase II data for microbiome therapy ...

The layoffs will not spare Generation’s R&D team, which will initially be retained while the biotech completes its strategic ...

Citing other priorities—such as the upcoming U.S.-Russia summit—four anonymous sources claim that pharma tariffs could still ...

Novo Nordisk has plummeted back to Earth after a stunning rise driven by Ozempic and Wegovy. Can the storied Danish pharma ...